Policy networks in health care policy: a case study on the National Institute for Clinical Excellence and the appraisal for Beta-Interferon.
Name of researcher:
Miss Theodora Kostikou, PhD student, Health Services Management Centre, University of Birmingham
I confirm that I have read and understand the information sheet dated ………..…for the above study and had the opportunity to ask question
Yes / No
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason
Yes / No
I know that records relating to me will be kept confidential. No information will be released or printed that would identify me.
Yes / No
I am happy for the interview to be taped recorded. Yes / No
I agree to take part in the above study. Yes / No
Name of participant: Date Signature
Researcher: Date Signature
178
APPENDIX G
List of analyzed documents
1. ABPI statement (2002) Agreement on provision of MS medicines. http://www.abpi.org.uk/press/press%20releases_02/020204.hm 2. Advances in Clinical Neuroscience and Rehabilitation (2001) NICE
denounced in MS Society campaign
3. Anon (1/11/2001) “Risk Sharing” among options to break MS drug deadlock
4. Anon (18/5/2001) Sufferers confront MP over MS drug
5. Anon (1999) NICE delay for Beta-interferons. Scrip 234; 2483:2 (22nd Oct) 6. Anon (22/1/?) Lewisham News Shopper Fury over MS drug holds up 7. Anon (23/6/2002) UK drug body launches review after MS controversy 8. Anon (6/2001) Not so easy for NICE Health Insight
9. Anon (9/8/2001) Wales should go it alone on beta interferon if necessary 10. Anon MS patients‟ campaign for greater access to beta interferon Pharmaco
EconOutcomes News 234:11 (16 Oct)
11. BBC News (10/12/1999) MS drug „should be restricted‟ http://news.bbc.co.uk/1/hi/health/556894.stm
12. BBC News (10/12/200) D-days nears for MS drugs
http://news6.thdo.bbc.co.uk/hi/english/health/newsid%5F1061000/1061967. stm
13. BBC News (11/7/2000) MS drug „cheaper than care‟ 14. BBC News (2002) Sufferers welcome MS drug Deal
179
http://news.bbc.co.uk/hi/english/uk/scotland/newsid_1800000/1800717.sm 15. BBC News (2002) Thousands to get MS drugs
http://news.bbc.co.uk/hi/english/uk/scotland/newsid_1800000/1800163.stm
16. BBC News (21/6/2000) Should the NHS provide MS drug? Beta Interferon can reduce the severity of MS attacks.
http://news.bbc.co.uk/1/hi/health/800068.stm 17. BBC News (24/6/2000) MS patients denied Talks.
http://news.bbc.co.uk/1/hi/health/803344.stm
18. BBC News (25/1/2000) MS drug „not worth the money‟
19. BBC news (25/9/2000) Beta Interferon case boosted by research. UK. http://news.bbc.co.uk/1/hi/health/941812.stm
20. BBC News (31/10/2001) NICE admits plans to ban beta interferon
21. BBC News (4/2/2002) Government proposes clinical trials of beta interferon 22. BBC News (7/8/2001) Concern as MS drug „rationed‟. UK.
http://news.bbc.co.uk/1/hi/health/1476084.stm
23. BBC News Online (6/8/2001) „Beta interferon is my last hope‟. http://news.bbc.co.uk/1/hi/health/1476002.stm
24. BBC News (11/7/2000) Misleading cost calculation
25. BBC News Sci/Tec (10/5/1998) New Hope for MS sufferers. http://news.bbc.co.uk/1/hi/sci/tech/90541.stm
26. Bellingham, C. (2001) NICE and MS: the saga will continue. News Feature. The Pharmaceutical Journal vol 267; 7173:672
27. Boseley, S. (30/4/2001) Drug cost dithering „lets MS get worse‟. NHS quality and performance
180
28. Brindley, M. (2001) MS Sufferer wants answer on NHS lottery. Western Mail http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=698 29. Butler, P. (31/10/2001) New Hope for MS sufferers. NHS quality and
performance
30. Caines, E. (2000) When NICE turns nasty. The Source Public
Management Journal. http://www.sourceuk.net/article/0/ 684/when nice _turns nasty.html
31. Charatan, F. Interferon treatment is beneficial in early MS? BMJ vol 321; 7265:851 http://bmj.bmjjournals.com/cgi/reprint/321/7265/851/a
32. Davis, H. (2000) You have got it wrong Minister. BBC News
33. Dobson, R. (2000) NICE to consider evidence on beta interferon. BMJ vol 321:1244
34. Dyer, C (1997) Ruling on interferon beta will hit all health authorities. BMJ 315(7101):146 http://www.bmj.com/cgi/content/full/315/7101/143/g
35. Eeles, J. (2001) Dithering over drugs. Reader‟s letter. www.societyguardian.co.uk
36. Forbes, R.B. et al. (1999) Population based cost utility study of interferon beta -1b in SPMS. BMJ vol 319:1529-1533
37. Green, B. and Mynes, S. (1999) Issues in Multiple sclerosis. The Pharmaceutical Journal, vol 262; 7045:699-701
38. Guardian (4/5/2001) NICE or nasty? MS sufferers must wait and see 39. Harrison, D. (2001) Beta Interferon. At long last- light at the end of the
tunnel? Newsletter #5. MS Society Scotland
181 Observer
41. Kendrick, M. and Johnson, K.I. (2000) Long-term treatment of multiple sclerosis with beta interferon may be cost effective. PharmacoEcon 2000; 18:45-53 Scrip 2000; 2558: 4
42. Little, R. (2002) NHS to fund treatment for 100000 patients with MS. BMJ vol 324:316
43. Mayor, S. (2001) Health Department to fund Beta Interferon despite Institute‟s ruling.BMJ vol 323:1087
44. McDermid, A. Double blow for MS sufferers. The Pharmaceutical Journal vol265; 7122:712
45. MS Charities cooperation Leaflet on Beta Interferon treatment. http://www.geocities.com/swanfield/beta.html
46. MS treatments: ABC Drugs, is there a cure for MS? ttp://www.multsclerosis.org/ABCtreatments.html
47. MS Week (12/4/2000) Response to Catrin Williams at Scunthorpe Evening Telegraph
48. Nelson, B. (2000) MS sufferer‟s anger over threat to „wonder drug‟ 49. News Archive (2000) NICE multiple sclerosis guidance delayed until next
year [online] Available from: http://www.pharmaceutical-journal.com/nice- multiple-sclerosis-guidance-delayed-until-next-year/20003516.article 50. News Archive (2000) Not so NICE!
http://www.pharmaceuticaljournal.com/searcharticles?keywords=Not+so+N ICE&PageNo=1&cmd=ChangeSortOrder&val=2
182
http://www.pharmaceutical-journal.com//20004065.article
52. News Archive (2000) New Research shows great benefit of beta interferon for MS http://www.pharmaceutical-journal.com/learning/cpd-
article/multiple-sclerosis-the-disease-and-its-treatment/20001379.article 53. NICE (2002) Beta Interferon and glatiramer acetate for the treatment of
multiple sclerosis. Technology appraisal no 32. London
54. NICE Press Release 2000/019 (2000) Appraisal of beta interferon and glatimer for Multiple Sclerosis. www.nice.org.uk/article.asp?a=1352 55. NICE Press Release 2000/020 (2000) Beta interferon/ glatimer speculation.
www.nice.org.uk/article.asp?a=1370
56. NICE Press Release 2001/007 (2002) NICE issues guidance on drugs for multiple sclerosis. www.nice.org.uk
57. NICE Press Release 2001/03 (2002) Appeal Decision: Technology appraisal on the use of beta interferon and glatimer. www.nice.org.uk
58. NICE Press Release 2001/29 (2001) Appraisal of beta interferon and glatimer for Multiple Sclerosis. www.nice.org.uk
59. NICE under Fire, 2000. www.sourceuk.net
60. Pharmafocus, (25/01/2002) Growing consensus‟ over split in NICE roles. http://pharmafile.com/ Pharmafocus/News/Story.asp?sID=2150&M=1 61. Pharmafocus, (29/1/2002) Companies look to „risk sharing‟ as final NICE
appeal fails.
http://pharmafile.com/Pharmafocus/News/Story.asp?sID=2152&M=1 62. Reuters London. British MS Society urges long-term study of MS drugs 63. Squaring the Circle: Will NICE and the other solve the problem? www.ms-
183 uk.org/files/npwm_2000_0004.pdf
64. Teva Pharmaceuticals Ltd. Press release. (5/2/2002) Copaxone becomes available to UK MS patients under NHS scheme. Jerusalem
65. The Hertfordshire & Essex Region of the MS Society (2001) NICE appraisal of disease modifying drugs in MS-an update
66. Timmins, N. (26/1/2002) Payment for MS drug linked to its success. Financial Times
67. Timmins, N. (4/2/2002) NHS makes ground breaking deal. Financial Times 68. Timmins, N. (5/2/2002) makers cut cost of MS drugs for NHS. Financial
Times
69. Tompkins, M. (2000) B-interferon use in the treatment of MS
70. Trentham, K. (1999) Multiple Sclerosis. National Institute for Medical Research London.UK
71. MS Society (2001) NICE has „turned its back on people with MS‟ 72. Woodman, R. (2000) UK Group offers plan to get MS drugs to patients.
London. Reuters Health.
184
APPENDIX H: EVALUATION FORM